Incyte
INCY
503 hedge funds and large institutions have $18.8B invested in Incyte in 2017 Q4 according to their latest regulatory filings, with 82 funds opening new positions, 189 increasing their positions, 180 reducing their positions, and 72 closing their positions.
14% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 72
1.86% more ownership
Funds ownership: 91.98% → 93.84% (+1.9%)
1% more funds holding
Funds holding: 496 → 503 (+7)
5% more repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 180
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
17% less capital invested
Capital invested by funds: $22.6B → $18.8B (-$3.86B)
33% less call options, than puts
Call options by funds: $213M | Put options by funds: $316M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$739M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
+$101M |
| 3 |
Goldman Sachs
New York
|
+$84.1M |
| 4 |
Renaissance Technologies
New York
|
+$79.1M |
| 5 |
HM
HealthCor Management
New York
|
+$78.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$172M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$147M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$120M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$89M |
| 5 |
Jennison Associates
New York
|
-$83.8M |
INCY Hedge Fund Activity: Q4 2017 in Review
503 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Incyte (INCY) for Q4 2017, worth a combined $18.8B — down 17% from $22.6B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new INCY positions and 72 closed out — a net gain of 10 holders — while 189 added to existing stakes and 180 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $739M. The largest seller was OrbiMed, exiting entirely with an estimated $172M sold.
- 503 institutional investors held Incyte (INCY) as of Q4 2017, up from 496 in Q3 2017.
- Funds reported $18.8B of Incyte stock for Q4 2017, down 17% quarter-over-quarter.
- 82 funds opened new Incyte positions in Q4 2017 and 72 closed out, a net change of +10 holders.
- The largest Incyte buyer in Q4 2017 was T. Rowe Price Associates, an estimated $739M added.
- The largest Incyte seller in Q4 2017 was OrbiMed, an estimated $172M sold.
Based on aggregated 13F filings for Q4 2017.